标题：人胃癌组织中生长抑制因子p33ING1的表达及其与患者临床病理参数的关系

      作者：张余黄 1，殷鹏飞 1，姚书鹏 2    安康市中心医院消化科 1、普外二科 2，陕西 安康 725000

      卷次： 2019年30卷22期

      【摘要】 目的 探讨人胃癌组织中生长抑制因子 p33ING1的表达及其与胃癌患者临床病理参数之间的关系。方法 选取安康市中心医院2014—2018年行胃癌切除术切除的石蜡标本153例为研究对象，其中有胃癌组织83例(胃癌组)，正常胃黏膜组织32例(正常组)，不典型增生胃黏膜组织38例(不典型增生组)。通过免疫组织化学法检测所有标本组织中p33ING1蛋白的表达情况，收集所有患者临床病理资料及生存状态，并行相关分析。结果 正常组中p33ING1蛋白的阳性率为100.00%，明显高于不典型增生组的63.16%和胃癌组的36.14%，差异均具有统计学意义(P<0.05)；胃癌组中分化程度Ⅰ级、Ⅱ级、Ⅲ级患者的p33ING1阳性率分别为66.67%、51.43%、34.48%，分化程度Ⅰ级的p33ING1阳性率高于Ⅱ级，Ⅱ级高于Ⅲ级，差异均具有统计学意义(P<0.05)；而黏膜下层、肌层、浆膜层p33ING1阳性率分别为80.00%、55.56%、36.36%，黏膜下层p33ING1阳性率高于肌层、浆膜层，肌层p33ING1阳性率高于浆膜层，差异均具有统计学意义(P<0.05)；淋巴结无转移者的 p33ING1阳性率为62.5%，明显高于有转移者的31.37%，差异具有统计学意义(P<0.05)；临床分期Ⅰ期、Ⅱ期、Ⅲ期患者的p33ING1阳性率分别为72.73%、43.33%、32.26%，Ⅰ期p33ING1阳性率高于Ⅱ期、Ⅲ期，差异均有统计学意义(P<0.05)；黏膜下层、肌层、浆膜层患者的生存率分别为 100.00%、57.14%、25.21%，黏膜下层生存率高于肌层、浆膜层，肌层生存率高于浆膜层差异有统计学意义(P<0.05)；淋巴结无转移者的生存率为52.38%，明显高于有转移者的14.68%，差异具有统计学意义(P<0.05)。结论 胃癌组织中生长抑制因子p33ING1表达异常，表达水平与细胞分化程度、浸润深度、淋巴转移和临床分期有关。
      【关键词】 生长抑制因子；胃癌；淋巴转移；免疫组织化学法；相关性
      【中图分类号】 R735.2 【文献标识码】 A 【文章编号】 1003—6350（2019）22—2890—04

Expression of growth inhibitory factor p33ING1 in human gastric carcinoma and its relationship withclinicopathological parameters in patients with gastric cancer.
ZHANG Yu-huang 1, YIN Peng-fei 1, YAO Shu-peng 2.Department of Gastroenterology 1, Department of General Surgery 2, Ankang Central Hospital, Ankang 725000, Shaanxi,CHINA
【Abstract】 Objective To investigate the expression of growth inhibitory factor p33ING1 in human gastric carci-noma and its relationship with the clinicopathological parameters of gastric cancer. Methods A total of 153 paraffinsamples of patients with gastric cancer from Ankang Central Hospital who underwent gastrectomy from 2014 to 2018were selected as research objects, including 83 samples of gastric cancer, 32 samples of normal gastric mucosa and 38samples of atypical hyperplasia. Immunohistochemical method was used to detect the expression of p33ING1 protein. Theclinicopathological data and survival status of all patients were collected and analyzed for correlation. Results The pos-itive rate of p33ING1 in the normal group was 100.00%, which was significantly higher than 63.16% in the atypical hyper-plasia group or 36.14% in the gastric cancer group (P<0.05). The positive rate of p33ING1 were 66.67%, 51.43%, 34.48%in gastric cancer of gradeⅠ,Ⅱ, andⅢ period, with the rate significantly higher in gradeⅠperiod than gradeⅡ periodand in grade Ⅱ period than grade Ⅲ period (P<0.05). The positive rate of p33ING1 in submucosa, muscularis, and serosalayer were 80.00%, 55.56%, 36.36%, with statistically significant differences (P<0.05). The positive rate of p33ING1 in pa-tients without lymph node metastasis was 62.5%, significantly higher than 31.37% in patients with lymph node metasta-sis (P<0.05). The positive rates of p33ING1 in patients of clinical stage Ⅰ period, Ⅱ period, Ⅲ period were 72.73% ,43.33%, 32.26%, with the rate significantly higher in Ⅰperiod than in Ⅱ period or Ⅲ period (P<0.05). The survivalrates of submucosa, muscularis, and serosa were 100.00%, 57.14% and 25.21%, respectively, with significant differencesamong the three (P<0.05). The survival rates in patients without lymph node metastasis was 52.38%, significantly higherthan 14.68% in patients with lymph node metastasis (P<0.05). Conclusion The expression of growth inhibitory factorp33ING1 was abnormal in gastric carcinoma, and the expression level was related to the degree of cell differentiation,depth of invasion, lymphatic metastasis, and clinical stage.
      【Key words】 Growth inhibitory factor p33ING1; Gastric cancer; Lymphatic metastasis; Immunohistochemical meth-od; Correlation